New England Hemolytics appoints Hayden Jeffreys as a Non-Executive Director

Guilford CT, USA – 12 June 2023: New England Hemolytics, a leading Fully Automated Sample Prep System company for Direct-from-Blood, No-culture Diagnostic Assays has appointed Hayden Jeffreys as a Non-Executive Director and board member.  Mr Jeffreys has held a variety of C-suite roles from his most recent position as COO of AIM listed Yourgene and President of Yourgene Inc as well as CEO of NYSE listed Erba Diagnostics and the Vice President of Corporate Development for Erba Mannheim. John Noble, Chief Executive Officer, commented: "I am delighted to welcome Hayden on board, he has a wealth of commercial and operational experience that will help position the business for growth in the coming years. I am also pleased that he brings many years of fundraising experience from the private and public markets in the US as well as the UK. " New England Hemolytics John Noble, Chief Executive Officer

About New England HemolyticsNew England Hemolytics is a leading Fully Automated Sample Prep System company for Direct-from-Blood, No-culture Diagnostic Assays. New England Hemolytics has invented a novel and transformative blood processing technology which they have incorporated into a revolutionary new automated clinical lab instrument that can rapidly extract pathogens and their DNA from venous whole blood samples with very high efficiency, thus enabling rapid and effective molecular diagnostic solutions for low-concentration blood-borne infections such as sepsis and Lyme disease.  The US healthcare system spends over $20B per year treating patients with sepsis.  Despite this, the rapid, accurate, and specific diagnosis of sepsis is still a largely unaddressed medical need and is estimated to be a $3.4B market in the U.S.    The NEH sample preparation technology and instrument will enable downstream molecular diagnostic assays such as PCR and isothermal DNA amplification based-detection/identification, and eventually DNA sequencing. New England Hemolytics leadership team has over 80 years of combined experience in instrument, kit, and diagnostic assay development. For more information visit